Dose and timing : the pillars of successful chemotherapy
著者
書誌事項
Dose and timing : the pillars of successful chemotherapy
（European School of Oncology scientific updates, v. 3）
Elsevier, 1998
大学図書館所蔵 件 / 全7件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes index
内容説明・目次
内容説明
In November 1997, a Task Force meeting was held in Milan on behalf of the European School of Oncology, during which various aspects of the role of dosage and timing of chemotherapy in solid tumours and lymphomas were discussed by a panel of experts. The present volume is concerned with some of the major topics in the fascinating and still only partially understood and developed field of medical oncology and haematology. Uncertainties and doubts continue to exist despite nearly twenty years of investigation into the subject of dosage and timing of drug delivery. In the last few years, thousands of patients in Europe as well as the United States have received high-dose chemotherapy supported by haematopoietic rescue, although conflicting data still prevail in this area. The tendency towards the administration of higher doses might originate from the lack of breakthroughs in cancer treatment in the last decade, as well as from the revolutionary introduction into clinical practice of haematopoietic progenitor cells, and from phase II (many) and phase III (few) studies. Nevertheless, high-dose chemotherapy is not the only way to deliver "more".
This book will inform the reader about what has been achieved, the state of current research and expected directions in research in the near future, as far as dosage and timing are concerned. It is not intended to be an apology for high-dose treatment but rather a serious and critical overview of knowledge.
目次
Introduction (G. Rosti). Evidence in favour of single or two courses of high-dose chemotherapy with peripheral blood progenitor cell transplantation in breast cancer (R.D. Baynes et al.). The importance of dose and time in the treatment of breast cancer (D.A. Cameron, R.C.F. Leonard). Long-term disease-free survival in disseminated breast cancer patients treated with conventional and high-dose chemotherapy: predictive factors and therapeutics implications (M. Martin et al.). High-dose chemotherapy with progenitor cell rescue in patients with lymphomas and solid tumors: what is believed and what is known? (D.K. Hossfeld). Dose and time: a crucial factor in high-grade lymphoma (M. Reiser et al.). The importance of dose and time: example of testicular cancer (S. Culine). Ongoing studies and the EBMT database (G. Rosti et al.). Timely chemotherapy in lung cancer: the proper dose at the proper time (T.A.W. Splinter). The importance of dose and time: example of soft tissue sarcoma and osteosarcoma (H. Dumez, A.T. van Oosterom). Is chemotherapy dose an important determinant of treatment outcome? (M. Hernandez-Bronchud). Subject index.
「Nielsen BookData」 より
